Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanabecestat in mild Alzheimer's disease
NCT02783573Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Jul 2016
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of lanabecestat in Alzheimer's disease (AD), sponsored by AstraZeneca. Started Jul 2016; status: terminated.
02
Drugs
lanabecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02783573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02783573.